Miravant Photrex confirmatory trial begins
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Miravant is initiating a 600-patient confirmatory trial of its macular degeneration therapy Photrex (rostaporfin, SnET2), the firm says March 10. The FDA-requested trial's design, reviewed under a special protocol assessment, will evaluate a range of patients with wet age-related macular degeneration, including both classic and occult lesions" (1Pharmaceutical Approvals Monthly February 2005, p. 16)...